Revvity, Inc. (RVTY) Total Return CAGR:4.19%(TTM)
Over the latest trailing 12-month period, Revvity, Inc. (RVTY)'s total return cagr is +4.19%. The comparable SPY value is +26.21%. Year-to-date total return is +1.24%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Revvity, Inc.'s Total Return CAGR averages -6.13% over 3 years and -7.94% over 5 years. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of Revvity, Inc.'s investment performance.
RVTY Total Return CAGR Chart
Revvity, Inc. (RVTY)
RVTY Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
RVTY Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 1330.14 | 1346.69 | +16.55 | +1.24% | +1.24% |
| 2025 | 1530.07 | 1330.14 | -199.93 | -13.07% | -13.07% |
| 2024 | 1494.65 | 1530.07 | +35.42 | +2.37% | +2.37% |
| 2023 | 1912.90 | 1494.65 | -418.25 | -21.86% | -21.86% |
| 2022 | 2737.77 | 1912.90 | -824.87 | -30.13% | -30.13% |
| 2021 | 1950.41 | 2737.77 | +787.37 | +40.37% | +40.37% |
| 2020 | 1316.12 | 1950.41 | +634.29 | +48.19% | +48.19% |
| 2019 | 1061.33 | 1316.12 | +254.78 | +24.01% | +24.01% |
| 2018 | 984.51 | 1061.33 | +76.83 | +7.80% | +7.80% |
| 2017 | 698.98 | 984.51 | +285.53 | +40.85% | +40.85% |
| 2016 | 714.11 | 698.98 | -15.13 | -2.12% | -2.12% |
| 2015 | 579.57 | 714.11 | +134.55 | +23.21% | +23.21% |
| 2014 | 542.90 | 579.57 | +36.67 | +6.75% | +6.75% |
| 2013 | 414.56 | 542.90 | +128.34 | +30.96% | +30.96% |
| 2012 | 258.43 | 414.56 | +156.13 | +60.41% | +60.41% |
| 2011 | 329.72 | 258.43 | -71.29 | -21.62% | -21.62% |
| 2010 | 259.55 | 329.72 | +70.17 | +27.04% | +27.04% |
| 2009 | 172.27 | 259.55 | +87.28 | +50.67% | +50.67% |
| 2008 | 318.56 | 172.27 | -146.29 | -45.92% | -45.92% |
| 2007 | 269.19 | 318.56 | +49.36 | +18.34% | +18.34% |
| 2006 | 281.61 | 269.19 | -12.42 | -4.41% | -4.41% |
| 2005 | 265.20 | 281.61 | +16.41 | +6.19% | +6.19% |
| 2004 | 198.22 | 265.20 | +66.99 | +33.79% | +33.79% |
| 2003 | 93.46 | 198.22 | +104.76 | +112.10% | +112.10% |
| 2002 | 384.65 | 93.46 | -291.19 | -75.70% | -75.70% |
| 2001 | 571.79 | 384.65 | -187.14 | -32.73% | -32.73% |
| 2000 | 224.92 | 571.79 | +346.86 | +154.22% | +154.22% |
| 1999 | 147.50 | 224.92 | +77.42 | +52.48% | +52.48% |
| 1998 | 107.93 | 147.50 | +39.58 | +36.67% | +36.67% |
| 1997 | 101.50 | 107.93 | +6.42 | +6.33% | +6.33% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 1,347 | +12.3% | +0.3% |
| Q1 2026 | 1,199 | -10.5% | -18.6% |
| Q4 2025 | 1,339 | +15.8% | -11.6% |
| Q3 2025 | 1,157 | -13.9% | -33.2% |
| Q2 2025 | 1,343 | -8.8% | -8.6% |
| Q1 2025 | 1,473 | -2.8% | +2.5% |
| Q4 2024 | 1,515 | -12.6% | +1.1% |
| Q3 2024 | 1,733 | +18.0% | +14.4% |
| Q2 2024 | 1,469 | +2.3% | -7.2% |
| Q1 2024 | 1,437 | -4.2% | -15.9% |
| Q4 2023 | 1,499 | -1.1% | -23.1% |
| Q3 2023 | 1,515 | -4.3% | -8.2% |
| Q2 2023 | 1,584 | -7.2% | -17.8% |
| Q1 2023 | 1,707 | -12.4% | -29.1% |
| Q4 2022 | 1,949 | +18.1% | -25.3% |
| Q3 2022 | 1,650 | -14.3% | -34.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh